Related by context. All words. (Click for frequent words.) 83 pT3 76 T1a 76 underwent resection 75 radical prostatectomy RP 74 T1c 74 urothelial carcinoma 74 completely resected 73 nonmetastatic 73 neoplasias 73 prostate carcinoma 73 extracapsular extension 73 seminal vesicle invasion 72 Papillary 72 underwent surgical resection 72 Histologic 72 nodal metastasis 72 invasive carcinomas 72 localized renal 71 CIN2 + 71 stage IIIB 71 lymphadenectomy 71 lymph node metastasis 71 prostate cancer CaP 71 thymoma 71 histologically confirmed 71 intraepithelial neoplasia 71 histopathologic examination 71 Adenomas 71 adjuvant radiotherapy 71 intravesical therapy 70 biochemical relapse 70 advanced adenoma 70 leiomyomas 70 resectable 70 mucinous 70 hepatocellular carcinomas 70 pCR 70 lymph node metastases 70 metastatic malignant 70 gastric adenocarcinoma 70 pancreatic adenocarcinoma 70 breast carcinoma 70 PCa 70 surgically resected 70 colorectal carcinoma 70 biochemical recurrence 70 NMIBC 69 pathologic diagnosis 69 LHRH receptor positive 69 thyroid carcinoma 69 bone scintigraphy 69 colorectal neoplasms 69 locoregional recurrence 69 F FDG PET 69 thyroglobulin 69 ASCUS 69 FDG-PET/CT 69 elevated LDH 69 histologic subtype 69 transvaginal sonography 69 intestinal metaplasia 69 biliary tract cancer 69 visceral metastases 69 perineural invasion 69 metaplasia 69 bladder carcinoma 69 FDG PET imaging 69 Immunohistochemical staining 69 endoscopic ultrasonography 69 HGPIN 69 lymphocytosis 69 VATS lobectomy 69 pulmonary metastases 69 haematologic 69 situ LCIS 69 invasive ductal 69 epithelial tumors 69 pelvic lymphadenectomy 69 neoadjuvant therapy 69 EBUS FNA 69 preoperative PSA 69 papillary thyroid carcinoma 69 colorectal adenoma 69 advanced adenomas 69 CC genotype 68 ductal carcinomas 68 renal tumors 68 lobular carcinoma 68 total thyroidectomy 68 seropositivity 68 #F FDG PET 68 histological subtype 68 radical nephrectomy 68 undergoing radical cystectomy 68 CLL SLL 68 neoplasms 68 baseline LDH 68 immunostaining 68 metachronous 68 bronchoalveolar lavage 68 ErbB2 positive 68 breast carcinomas 68 chemoresistant 68 radical cystectomy 68 prostate adenocarcinoma 68 Stage IIB 68 lymphovascular invasion 68 castrate resistant 68 renal cell carcinomas 68 peritoneal carcinomatosis 68 pheochromocytoma 68 PSA nadir 68 neoadjuvant chemotherapy 68 nodal metastases 68 specific antigen PSA 68 metastatic gastric 68 multivariate analyzes 68 EUS FNA 68 transitional cell carcinoma 68 distant metastasis 68 recurrent glioblastoma multiforme 68 liver metastasis 68 SLNB 68 TRUS 68 Lymph node 68 pituitary adenomas 68 cystectomy 67 lymph node involvement 67 clinicopathological features 67 chemoradiation therapy 67 thymectomy 67 HBeAg 67 Prostatic 67 immunohistochemical analysis 67 Carcinoma 67 basal cell carcinoma BCC 67 gadolinium enhanced 67 adenomatous 67 histologic 67 Hurthle cell 67 paragangliomas 67 adrenalectomy 67 reflux esophagitis 67 seminoma 67 histologically proven 67 histologically 67 unresectable tumors 67 TIMP 67 pathologic examination 67 Adjuvant Chemotherapy 67 Endometrial 67 normal karyotype 67 liver resection 67 esophageal carcinoma 67 debulking surgery 67 metastatic malignant melanoma 67 papillary renal cell carcinoma 67 surgically resectable 67 grade cervical intraepithelial 67 hyperplastic 67 ultrasonographic 67 cutaneous melanoma 67 ovarian carcinoma 67 cytogenetic abnormalities 67 hilar 67 MALT lymphoma 67 grade squamous intraepithelial 67 Squamous 67 Histological 67 HNSCC 67 mesotheliomas 67 microsatellite instability 67 sarcomatoid 67 Neoplasms 67 undetectable HBV DNA 67 IV NSCLC 67 invasive lobular 67 ischemic lesions 67 NSCLC tumors 67 recurrent NSCLC 67 SUVmax 67 paraganglioma 67 hormone receptor negative 67 Retreatment 67 DAS# CRP 67 schwannomas 67 CIN3 67 underwent radical prostatectomy 67 cytoreduction 67 univariate analysis 67 skeletal metastases 67 Subgroup analysis 67 radiotherapy RT 67 endosonography 67 achieved CCyR 67 stage IIIb IV 67 Soft Tissue Sarcoma 67 prostatic adenocarcinoma 67 lymphadenopathy 67 pancreatic carcinoma 67 operable breast cancer 67 â ‰ ¥ 67 fallopian tube carcinoma 66 Immunohistochemical analysis 66 treat benign prostatic 66 Legg Calvé Perthes disease 66 Leukemias 66 malignant ascites 66 histological diagnosis 66 concurrent chemoradiation 66 K ras mutations 66 adenomatous polyps 66 EBRT 66 advanced neoplasia 66 Leydig cell 66 histologic findings 66 transabdominal 66 urothelial bladder cancer 66 Flu Cy 66 nondiabetic patients 66 TURBT 66 node metastases 66 atypical hyperplasia 66 cytologic 66 transurethral resection 66 CTEPH 66 malignant neoplasm 66 proctitis 66 Postoperative complications 66 malignant lymphoma 66 Castration Resistant Prostate Cancer 66 euthyroid 66 FluCAM arm 66 cervical intraepithelial neoplasia 66 follicular thyroid cancer 66 radical retropubic prostatectomy 66 urothelial cancer 66 tumor necrosis 66 TIMP 1 66 ^ sup #m 66 B Cell Lymphoma 66 median survivals 66 ertapenem 66 allogeneic hematopoietic stem cell 66 PEG IFN 66 leukemia AML 66 XIENCE V PROMUS Stent 66 perioperative complications 66 diabetes mellitus DM 66 endometrioid 66 subependymal giant cell 66 clinicopathological 66 histopathological 66 cytologically confirmed 66 HER2 overexpression 66 enterococcal 66 renal pelvis 66 HRCT 66 Peripheral Arterial 66 Preoperative 66 malignant ovarian 66 small lymphocytic lymphoma 66 intact parathyroid hormone 66 pretransplant 66 ALND 66 gastric carcinoma 66 preoperative chemotherapy 66 Doxil ® 66 Asymptomatic 66 laparoscopic radical nephrectomy 66 FOLFOX6 66 multivariable analysis 66 neoplasm 65 % CI #.#-#.# [003] 65 cytokeratin 65 squamous intraepithelial lesions 65 Allogeneic 65 benign neoplasms 65 nephron sparing surgery 65 Carcinomas 65 thyroid nodules 65 needle aspiration 65 cTnI 65 medically inoperable 65 macroalbuminuria 65 proximal colon 65 % CI #.#-#.# [008] 65 Cystectomy 65 HER2 amplification 65 retroperitoneal 65 Accelerated Partial Breast Irradiation 65 elevated transaminases 65 colorectal carcinomas 65 metastatic lymph nodes 65 radioiodine therapy 65 scintigraphic 65 ADPKD 65 serum prostate 65 rebleeding 65 cervical lymph node 65 % CI #.#-#.# [007] 65 bronchogenic carcinoma 65 #F FDG 65 adnexal mass 65 papillary carcinoma 65 primary hyperparathyroidism 65 prospective multicenter study 65 cholelithiasis 65 Estrogen Receptor 65 pleomorphic 65 Follicular Lymphoma 65 HBeAg negative 65 Partial Response 65 ara C 65 prostate carcinomas 65 lymphocytic 65 recurrent metastatic 65 International Prognostic Scoring 65 relapsed MM 65 Chemoradiation 65 CIN2 65 Adjuvant chemotherapy 65 EGFR mutation positive 65 epithelial ovarian 65 multivariate Cox 65 metastatic neuroendocrine tumors 65 polyposis 65 osteoid osteoma 65 Patients Treated With 65 hamartomas 65 HER2 expression 65 mediastinitis 65 malignant lesions 65 histopathologic 65 chemoradiotherapy 65 cholangiocarcinoma 65 IDH1 mutation 65 RECIST Response Evaluation Criteria 65 TNM staging 65 resected tumors 65 liver histology 65 thyroidectomy 65 Systemic Sclerosis 65 wedge resection 65 TRAIL R1 65 acute myeloid 65 endometrial carcinoma 65 resected pancreatic cancer 65 Angiographic 65 biopsy Gleason 65 orchiectomy 65 Lymphocytic 65 CR nPR 65 precursor lesions 65 resected 65 neoadjuvant 65 polycythemia vera essential thrombocythemia 65 transcranial Doppler ultrasound 65 colorectal metastases 65 demyelinating 65 cranial irradiation 65 seronegative 65 pulmonary resection 65 adenocarcinomas 65 postoperative chemotherapy 65 prostate cancer PCa 65 Multiple Myeloma MM 65 hematopoietic cancers 65 prospectively enrolled 65 severe neutropenia 65 nonsmall cell lung cancer 65 immunocompetent 65 polypoid 65 antigen PSA levels 65 underwent radical cystectomy 65 perioperative morbidity 65 PAOD 65 LRTI 65 radiographic findings 65 T2DM 65 cervical lymph nodes 65 artery stenosis 65 MR Angiography 65 gastrectomy 65 transrectal ultrasound guided 65 parathyroidectomy 64 Relapsing Remitting Multiple Sclerosis 64 cytoreductive surgery 64 PSADT 64 metastatic colorectal 64 HBeAg negative patients 64 extracranial 64 mediastinal 64 Alkaline Phosphatase 64 splenic 64 graft occlusion 64 GISTs 64 immunoreactivity 64 Anaplastic 64 myelodysplastic myeloproliferative diseases 64 follicular lymphomas 64 adenoma 64 gene polymorphism 64 SGPT 64 epithelial ovarian cancer 64 carotid stenosis 64 Renal Artery 64 pericardial effusion 64 endoscopic resection 64 interstitial brachytherapy 64 neutropaenia 64 invasive carcinoma 64 Ultrasonography 64 autologous SCT 64 endobronchial 64 immunohistochemical 64 fibroma 64 gastric cardia 64 hydronephrosis 64 malignant polyps 64 resistant hormone refractory 64 distant metastases 64 clinically localized prostate 64 situ CIS 64 neuritic 64 squamous histology 64 complete cytogenetic response 64 COL#A# 64 neoplasia 64 BARACLUDE ® 64 cervical carcinoma 64 vestibular schwannomas 64 syngeneic 64 metastatic renal cell carcinoma 64 clinicopathologic 64 tumor histology 64 axillary node 64 colorectal liver metastases 64 lymphoproliferative disorders 64 stage IIIA 64 Cystatin C 64 locoregional 64 benign nodules 64 mRCC 64 response pCR 64 duplex ultrasonography 64 CIN3 + 64 urine cytology 64 urothelial 64 squamous cell carcinoma SCC 64 metastatic RCC 64 TP# mutations 64 rs# [004] 64 PNET 64 papillary 64 serrated polyps 64 transthoracic 64 gemcitabine carboplatin 64 allogeneic HSCT 64 tumors GIST 64 HBeAg positive patients 64 MGUS 64 micrometastasis 64 mammographically 64 Radical prostatectomy 64 hepatic metastases 64 -#.# ± [002] 64 Renal Cell Carcinoma RCC 64 Ductal carcinoma 64 null mice 64 primary patency 64 mCi 64 sonographically 64 node dissection 64 Sentinel Lymph Node Biopsy 64 immunohistochemical staining 64 Kaplan Meier analysis 64 ductal cancer 64 peritoneal cancer 64 elevated troponin 64 para aortic 64 Hematologic 64 leukocytosis 64 ALT elevation 64 ductal adenocarcinoma 64 xenograft model 64 mammographic density 64 p = NS 64 mycosis fungoides 64 antibody titer 64 KRAS mutations occur 64 esophagogastroduodenoscopy 64 hepatorenal syndrome 64 lymphocyte counts 64 pulmonary metastasis 64 coronary stenosis 64 invasive aspergillosis 64 bacteraemia 64 % Confidence Interval 64 angiographically 64 histologic examination 64 mutated KRAS 64 supratentorial 64 BRCA1 mutation carriers 64 postoperative complication 64 CP CPPS 64 sonographically guided 64 atrophic gastritis 64 Prolongs Survival 64 LV dysfunction 64 Bacteremia 64 antithymocyte globulin 64 colorectal adenocarcinoma 64 Cardiotoxicity 64 neurological manifestations 64 AST ALT 64 nonproliferative 64 unfavorable cytogenetics 64 transarterial 64 RARP 64 resections 64 osteosarcomas 64 Microalbuminuria 64 malignant pleural mesothelioma 64 micafungin 64 endometrial hyperplasia 64 dysplastic 64 liposomal amphotericin B 64 metastatic bladder 64 thrombocytosis 64 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 64 precancerous cervical 64 HBeAg + 64 monoclonal gammopathy 64 BCR ABL mutations 64 Histopathological 64 neoplastic 64 curative resection 64 KRAS mutation 64 neuroendocrine carcinoma 64 Fine needle aspiration 64 Resection 64 #Gy 64 PHPT 64 logistic regression analysis 64 genotypic resistance 64 Subgroup analyzes 64 achieved ACR# 64 neoadjuvant treatment 64 recurrent GBM 64 Hormone Refractory Prostate Cancer 64 adenoma recurrence 64 esophagectomy 64 % CI #.#-#.# [005] 64 ductal lobular 64 rs# [001] 64 cerebral angiography 64 receiving highly emetogenic 63 cytologic examination 63 adjuvant radiation 63 Pharmacokinetics PK 63 IIIA NSCLC 63 progesterone receptor negative 63 Natalizumab 63 occlusive disease 63 multivariable adjusted 63 extramedullary 63 HSCT 63 carcinoid tumor 63 bronchoalveolar lavage BAL 63 pancreatic resection 63 aortic root replacement 63 cancer mCRC 63 sorafenib Nexavar 63 Hodgkin lymphoma HL 63 CsA 63 RRM1 63 sentinel lymph node biopsy 63 pancreatic islet cell 63 Stomatitis 63 ductal breast cancer 63 mL/min/#.# m 2 63 gastrointestinal stromal tumors GIST 63 #q#.# [001] 63 Surgical resection 63 FDG uptake 63 abacavir Ziagen 63 Coronary Artery Bypass Graft 63 NSABP B 63 Progenitor Cells 63 TOP2A 63 leukocyte count 63 abdominal computed tomography 63 hypervascular 63 lymph node dissection 63 TNM classification 63 sensory neuropathy 63 KRAS wild 63 posterolateral fusion 63 HBeAg seroconversion 63 neoplastic lesions 63 contralateral breast 63 null responder 63 hematological relapse 63 Histopathologic 63 idiopathic PAH 63 intraductal 63 NRTI resistance 63 hepatic cirrhosis 63 undergone radical prostatectomy 63 Actinic Keratosis 63 Mitomycin C 63 rFSH 63 postoperative morbidity 63 TMPRSS2 ERG 63 tPSA 63 partial remissions 63 gefitinib Iressa 63 dysplastic nevi 63 definite stent thrombosis 63 flutamide 63 HER2 amplified 63 postintervention 63 Metastatic Prostate Cancer 63 adjuvant cisplatin 63 nasopharyngeal carcinoma 63 Metastases 63 Stent thrombosis 63 Interferon Beta 63 Glioblastoma Multiforme 63 #:#-# [031] 63 ß blockers 63 BRAF V#E mutation 63 Postoperative 63 Group RTOG 63 HGD 63 tumor xenograft models 63 p ≤ 63 systemic amyloidosis 63 rheumatoid factor 63 evaluable subjects 63 CCyR 63 carcinomatosis 63 anal intraepithelial neoplasia 63 carcinoembryonic antigen 63 BRAF V#E 63 heterozygotes 63 IIIb 63 cisplatin resistant 63 monocytic 63 hematologic abnormalities 63 MCyR 63 dorsal root ganglion 63 oncologic outcomes 63 Cell Lymphoma 63 lactate dehydrogenase 63 abdominal hysterectomy 63 endometrial adenocarcinoma 63 lymphoid malignancies 63 S aureus 63 relapsed ALL 63 deep venous thromboses 63 upper endoscopy 63 Prognostic factors 63 Neoadjuvant 63 polycythemia vera PV 63 Recurrence 63 Clusterin 63 EBUS TBNA 63 FDG PET 63 intracerebral 63 fosbretabulin 63 LV ejection fraction 63 Circulating tumor cells 63 retrospectively analyzed 63 mutated K ras 63 de novo AML 63 TUNEL 63 cardiac troponin T 63 BRCA1 BRCA2 63 vulvar intraepithelial neoplasia 63 extranodal 63 pheochromocytomas 63 ABL1 63 intrahepatic 63 Placebo Controlled Trial 63 idiopathic myelofibrosis 63 squamous 63 REYATAZ r arm 63 Critical Limb Ischemia CLI 63 Patency 63 mg BID dose 63 C. trachomatis 63 untreated metastatic melanoma 63 smoldering myeloma 63 Myelodysplastic Syndrome MDS 63 Adenocarcinoma 63 sirolimus stent 63 surgical debulking 63 Lenalidomide 63 prognostic factor 63 sleeve lobectomy 63 renal carcinoma 63 moderately emetogenic 63 multicenter randomized controlled 63 osteopenic 63 malignant nodules 63 Epidermal Growth Factor Receptor 63 transplantation HCT 63 patients undergoing CABG 63 Subtypes 63 Cancer Res 63 dacarbazine DTIC 63 myocardial necrosis 63 cytoreductive nephrectomy 63 aplasia 63 essential thrombocythemia ET 63 TKAs 63 cytomegalovirus infection 63 thrombocytopenic 63 androgen deprivation 63 adjuvant trastuzumab 63 Metastatic breast cancer 63 Multivariate analysis 63 Preoperatively 63 parathyroid carcinoma 63 Virologic 63 aminotransferase 63 orthotopic 63 MACCE 63 Thrombotic 63 anaplastic astrocytomas 63 acute cholecystitis 63 myeloproliferative disorder 63 hip resurfacing arthroplasty 63 IOP lowering 63 collagenous colitis 63 Nilotinib 63 anastrazole 63 diagnosing coronary artery 63 CYT# potent vascular disrupting 63 infliximab etanercept 63 polyp recurrence 63 ERalpha 63 metastatic lesions 63 posttreatment 63 abnormal cytology 63 cytogenic 63 Partial Responses 63 pretest probability 63 pneumonectomy 63 parathyroid 63 neuroblastoma tumors 63 ABCB1 63 Waldenstrom macroglobulinemia 63 percutaneous drainage 63 axillary node dissection 63 univariate analyzes 63 serous ovarian cancer 63 unresectable 63 complement inhibitor eculizumab 63 perioperative mortality 63 lymphomas leukemias 63 Renal Cell Carcinoma 63 #.#ng/ml 63 superficial bladder cancer 63 stage IIIb 63 P = .# 63 extracolonic findings 63 pmol L 63 hormone receptor status 63 TPV r 63 CRp 63 Atypical Hemolytic Uremic Syndrome 63 BRCA deficient 63 GSTP1 63 sunitinib Sutent 63 pancreatic ductal adenocarcinoma 63 choriocarcinoma 63 del 5q 63 tumor recurrence 63 antiretroviral naïve 63 irreversible inhibitor 63 R0 resection 63 cutaneous squamous cell carcinoma 63 transthyretin amyloidosis 63 sCJD 63 KRAS oncogene 63 B7 H3 63 fluconazole resistant 62 paraneoplastic 62 atrioventricular block 62 p = #.# [003] 62 hemodynamically significant 62 STRIDE PD 62 lung carcinomas 62 hypointense 62 carcinoids 62 appendiceal 62 Squamous Cell Carcinoma 62 hematologic toxicity 62 Cytogenetic 62 excisional biopsy 62 nonalcoholic steatohepatitis NASH 62 #:#-# [033] 62 metastatic ovarian cancer 62 Metastatic Renal Cell Carcinoma 62 epoetin alpha 62 Medullary thyroid cancer 62 C#BL 6 mice 62 elevated ALT 62 cisplatin gemcitabine 62 Metastatic 62 varices 62 undergoing radical prostatectomy 62 Thymic 62 radioimmunotherapy RIT 62 abdominal irradiation 62 astrocytoma 62 demonstrated antitumor activity 62 Adjuvant therapy 62 histologic subtypes 62 hyperoxaluria 62 serum urate levels 62 sonographic findings 62 seminomas 62 Patients Receiving 62 comparator arm 62 HLA DR4 62 p# biomarker 62 lobectomy 62 CT Angiography 62 confidence interval #.#-#.# 62 leukoencephalopathy 62 Gleevec resistant 62 KRAS mutations 62 JAK2 V#F 62 DLTs 62 Adjuvant Treatment 62 granulomatous 62 HIV HCV coinfected 62 esophageal gastric 62 pathologic 62 ANCA associated 62 Ischemic 62 μmol L 62 revascularizations 62 HLA A2 62 locoregional disease 62 Sezary syndrome 62 Evaluable 62 hypophosphatemia 62 Immunohistochemistry 62 arteritis 62 postoperative radiotherapy 62 lung resection 62 hepatic lesions 62 Comorbidities 62 GRASPA ® 62 serum PSA 62 alanine aminotransferase 62 Invasive Breast Cancer 62 Median PFS 62 minimally symptomatic 62 Hycamtin ® 62 Malignancies 62 MGd 62 Stage IIIb 62 Thromboembolism 62 pelvic lymph node dissection 62 p# antigen 62 Relapsed Refractory 62 BRCA2 mutation carriers 62 cryptogenic 62 tumoral 62 Main Outcome Measure 62 adrenal masses 62 HER2 positive cancers 62 haematological 62 bullous 62 CIMZIA TM certolizumab pegol 62 Carotid Endarterectomy 62 morphometric vertebral fractures 62 aspartate aminotransferase 62 nephrectomy 62 IPAH 62 Figure 2C 62 neoplasia CIN 62 serological markers 62 aortic regurgitation 62 RALP 62 T#I [002] 62 Radical Prostatectomy 62 aneurysmal 62 interleukin IL -6 62 invasive lobular carcinoma 62 histopathologic findings 62 alkaline phosphatase ALP 62 Non Alcoholic Steatohepatitis 62 promoter methylation 62 prognostic biomarker 62 somatostatin analog 62 β blockers 62 multicentric 62 variceal hemorrhage 62 binary restenosis 62 HER2 negative 62 diagnostic biomarker 62 arteriography 62 Antiviral Therapy 62 Decitabine 62 FOLFOX4 62 hamartoma 62 Prostatectomy 62 lobular carcinomas 62 TT genotype 62 variant allele 62 external beam radiotherapy 62 murine model 62 Prospective Randomized Trial 62 Hyperlipidemia 62 differentiated thyroid 62 Endometrial Cancer 62 sinonasal 62 pegylated liposomal doxorubicin 62 Cardiac Troponin 62 bronchioloalveolar carcinoma 62 pretreatment serum 62 chronic eosinophilic leukemia 62 fallopian tube cancers 62 leiomyoma 62 antiphospholipid antibodies 62 portal vein thrombosis 62 anterior uveitis 62 Aneurysm Repair 62 Randomized Study 62 adjuvant tamoxifen 62 Her2/neu 62 core needle biopsy 62 lupus anticoagulant 62 subtrochanteric 62 laparoscopic partial nephrectomy 62 Ishak fibrosis score 62 Non Alcoholic Fatty 62 obstructive coronary artery 62 pamidronate 62 Univariate analysis 62 doxorubicin docetaxel 62 EBUS 62 Upregulation 62 Abstract Number 62 paclitaxel cisplatin 62 liver metastases 62 spontaneous bacterial peritonitis 62 HBeAg positive 62 Advanced Renal Cell 62 IV melanoma 62 urethral stricture 62 prostate TURP 62 mediastinal lymph nodes 62 Hypotension 62 Protease Inhibitors 62 Erlotinib 62 pg ml 62 BPS IC 62 urolithiasis 62 artery embolization 62 Parathyroid 62 degenerative lumbar 62 Small Intestine 62 follicular lymphoma FL 62 T2 lesions 62 radiochemotherapy 62 Tumor Response 62 sero positive 62 NIHSS 62 villous atrophy 62 virological response 62 mCRPC 62 sacrocolpopexy 62 HIV seropositive 62 external genital lesions 62 prospectively evaluated 62 renal biopsy 62 NGAL 62 tumor resection 62 histopathologic diagnosis 62 cGy 62 Anthracycline 62 ventricular myocardium 62 florbetaben 62 HoLEP 62 resectable pancreatic cancer 62 chest radiographs 62 tuberous sclerosis TS 62 Pooled Analysis 62 mCRC patients 62 tipranavir r 62 Pemetrexed